



Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbshilpa.com, Web: www.vbshilpa.com
CIN: L85110KA1987PLC008739

Dated: 25th Aug, 2023

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI-400 051

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.
Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Shilpa Medicare Ltd, Unit IV, Jadcherla, Telangana has cleared ANVISA Brazil, GMP inspection

This is to inform you that the Company's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana state has undergone a GMP inspection by ANVISA, Brazil starting 21st August 2023. The inspection has concluded successfully on 24th Aug 2023 without any observations.

The facility is involved in manufacturing, packaging, labelling and testing of finished dosage forms (sterile injections and non-sterile oral solids) for the treatment of various forms of cancer and adjuvant therapy.

This inspection is the third major regulatory inspection (after Russia and Canada), cleared by this Site in the past two years.

This inspection and subsequent approval will allow the company for the commercial distribution of products in Brazil market and enable approval of new applications for Brazil market.

The company remains committed to maintain the GMP status and quality standards as per the expectations and standards of Global Regulatory Authorities.

With Regards,

For **SHILPA MEDICARE LIMITED**

Ritu Tiwary
Company Secretary & Compliance Officer